David Mark Dror
Research Subjects
David Mark Dror has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Ruth Koren
Tel Aviv University, Rabin Medical Center, Petah Tikva, Israel
10 shared publications- Pradeep Panda
Micro Insurance Academy, New Delhi, India
6 shared publications Pradeep Panda
Micro Insurance Academy, New Delhi, India and Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands
5 shared publications- Ruth Koren
Felsenstein Medical Research Center, Tel Aviv University Sackler Faculty of Medicine, Ramat Aviv, Tel Aviv, Israel
5 shared publications Arpita Chakraborty
Micro Insurance Academy, New Delhi, India and Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands; Public Health Foundation of India, Gurgaon, India,
4 shared publicationsAtanu Majumdar
Micro Insurance Academy, New Delhi, India
4 shared publications
Latest Publications
- 8 October 2026
- Published by Springer Nature in Aequationes mathematicae
- Vol. 100 (6) , 89
Hyers–Ulam stability of the multiplicative separability condition on $[0, 1]^n$- 8 October 2026
- Published by Springer Nature in Aequationes mathematicae
- Vol. 100 (6) , 89
Hyers–Ulam stability of the multiplicative separability condition on $[0, 1]^n$- Open Access
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
The Dual-Benefit Threshold: Why No Transfer Replaces a Collective
A member of a community health pool pays every year and never claims. By insurance logic, she should be the first to leave. She often stays, and dual benefit is what holds her: her own return is worth more as the collective's output grows, a coupling measured by the cross-partial δ ≡ ∂²W/∂G∂M between collective output G and personal benefit M, zero when the benefit separates. The coupling changes who exits: under separability, the non-claimant leaves first; where the collective channels are legible and clear, the premium, she renews, so lemons selection switches off. Two results carry the paper. A pool retains a stable, positive membership if and only if δ exceeds a critical value δ*, at which the participation dynamics fold in a saddle-node bifurcation; where the collective channels are closed to the member, the non-claimants leave first, an unraveling like Akerlof's. And where δ > 0, what the collective adds differs across members by δ·G·ΔM, so no single cash transfer fits all, and the best one is out by half that gap: the coupling cannot be bought out. The testable content is about staying, not joining. Indian panel data show illness does not predict who joins, but delivered benefit does predict who stays, and a five-year Nepal renewal panel shows the claimant–non-claimant gap widening with tenure on the log-odds scale, the sign the coupling predicts.
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Dual-Benefit Threshold: Why No Transfer Replaces a Collective
A member of a community health pool pays every year and never claims. By insurance logic, she should be the first to leave. She often stays, and dual benefit is what holds her: her own return is worth more as the collective's output grows, a coupling measured by the cross-partial δ ≡ ∂²W/∂G∂M between collective output G and personal benefit M, zero when the benefit separates. The coupling changes who exits: under separability, the non-claimant leaves first; where the collective channels are legible and clear, the premium, she renews, so lemons selection switches off. Two results carry the paper. A pool retains a stable, positive membership if and only if δ exceeds a critical value δ*, at which the participation dynamics fold in a saddle-node bifurcation; where the collective channels are closed to the member, the non-claimants leave first, an unraveling like Akerlof's. And where δ > 0, what the collective adds differs across members by δ·G·ΔM, so no single cash transfer fits all, and the best one is out by half that gap: the coupling cannot be bought out. The testable content is about staying, not joining. Indian panel data show illness does not predict who joins, but delivered benefit does predict who stays, and a five-year Nepal renewal panel shows the claimant–non-claimant gap widening with tenure on the log-odds scale, the sign the coupling predicts.
- Open Access
- 19 May 2026
- Published by Elsevier in SSRN Electronic Journal
When Disagreement Looks Like Agreement: A Measurement-Theoretic Foundation for Consensus in Collective-Action Research
Measures of dispersion in the Gini family — Gini’s (1912) mutability index, Simpson’s diversity index, the Herfindahl–Hirschman index, and the Coefficient of Unalikeability used in recent consensus research — were designed for nominal-categorical data. Over two decades they have migrated, citation by citation, into survey research where the data are typically ordinal. The instrument did not change when the data type did. This paper makes three connected contributions. We axiomatise what an ordinal consensus measure must satisfy and exhibit two admissible measures of distinct functional form — the Tastle–Wierman (2007) entropy-based measure and a normalised-variance measure. We prove that no member of the Gini family meets the axioms. We derive the threshold from a coordination model of decision implementation: below a critical level, a deliberative decision cannot be sustained against member defection; above it, compliance is self-reinforcing. The threshold is the bifurcation point of the model, derived without a fitted parameter and given as a structural property of the population. We illustrate the framework on 339 group–year cells from an Indian community-based health insurance dataset. The Gini-family measure overstates consensus relative to the admissible measure in 48 per cent of cells in Women’s Empowerment cohesion data, and records moderate consensus on eight groups that are bipolarly polarised between non-adjacent ordinal categories. The same arithmetic that proves the exclusion theorem appears in the data.
- 19 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessWhen Disagreement Looks Like Agreement: A Measurement-Theoretic Foundation for Consensus in Collective-Action Research
Measures of dispersion in the Gini family — Gini’s (1912) mutability index, Simpson’s diversity index, the Herfindahl–Hirschman index, and the Coefficient of Unalikeability used in recent consensus research — were designed for nominal-categorical data. Over two decades they have migrated, citation by citation, into survey research where the data are typically ordinal. The instrument did not change when the data type did. This paper makes three connected contributions. We axiomatise what an ordinal consensus measure must satisfy and exhibit two admissible measures of distinct functional form — the Tastle–Wierman (2007) entropy-based measure and a normalised-variance measure. We prove that no member of the Gini family meets the axioms. We derive the threshold from a coordination model of decision implementation: below a critical level, a deliberative decision cannot be sustained against member defection; above it, compliance is self-reinforcing. The threshold is the bifurcation point of the model, derived without a fitted parameter and given as a structural property of the population. We illustrate the framework on 339 group–year cells from an Indian community-based health insurance dataset. The Gini-family measure overstates consensus relative to the admissible measure in 48 per cent of cells in Women’s Empowerment cohesion data, and records moderate consensus on eight groups that are bipolarly polarised between non-adjacent ordinal categories. The same arithmetic that proves the exclusion theorem appears in the data.
- Open Access
- 19 December 2025
- Published by MDPI AG in Encyclopedia
- Vol. 6 (1) , 1
Trinity Law Framework: Health Insurance Taxonomy
Despite seven decades of international commitment—from the 1948 Universal Declaration of Human Rights through SDG 3.8—universal health coverage remains stubbornly out of reach. Two billion people, predominantly informal sector workers, lack access to sustainable health insurance. This entry explains the underlying cause: sustainable health insurance requires specific behavioral and institutional conditions for collective action—conditions that existing health insurance models systematically fail to satisfy, thereby structurally excluding informal populations. The Trinity Law framework formalizes these conditions as three multiplicatively interacting requirements—Trust (T), Consensus (C), and Dual Benefit (DB)—expressed as S = T × C × DB. Empirical analysis of community-based health insurance schemes across 24 countries identifies a robust trust threshold (τ* ≈ 0.68) operating as a behavioral phase transition: below this level, cooperation collapses; above it, participation becomes self-sustaining. Cross-country evidence from 274 organizations across 155 countries confirms consensus thresholds (C* ≈ 0.59), while analysis of 158,763 observations validates dual benefit mechanisms. The multiplicative structure explains why partial reforms fail: weakness in any single component drives overall sustainability toward zero. Applied to health insurance, this framework distinguishes conventional systems—Bismarckian employment-based, Beveridgean tax-financed, and commercial health insurance from sustainable systems like participatory community-based microinsurance that satisfy all three Trinity Law conditions through participatory design, transparent governance, and aligned incentives. The persistent UHC gap reflects not implementation failures but fundamental design incompatibilities that the Trinity Law makes explicit. This entry has three objectives: first, it states the Trinity Law conditions; second, it summarizes the empirical evidence for each component; third, it applies the framework to classify major health insurance models. Supporting datasets and code are available in the referenced Zenodo repositories. The term ‘law’ follows the tradition of social science regularities like the ‘law of demand’: a robust empirical pattern with strong predictive validity, not a claim to physical certainty.
- 19 December 2025
- Published by MDPI AG in Encyclopedia
- Vol. 6 (1) , 1
Open AccessTrinity Law Framework: Health Insurance Taxonomy
Despite seven decades of international commitment—from the 1948 Universal Declaration of Human Rights through SDG 3.8—universal health coverage remains stubbornly out of reach. Two billion people, predominantly informal sector workers, lack access to sustainable health insurance. This entry explains the underlying cause: sustainable health insurance requires specific behavioral and institutional conditions for collective action—conditions that existing health insurance models systematically fail to satisfy, thereby structurally excluding informal populations. The Trinity Law framework formalizes these conditions as three multiplicatively interacting requirements—Trust (T), Consensus (C), and Dual Benefit (DB)—expressed as S = T × C × DB. Empirical analysis of community-based health insurance schemes across 24 countries identifies a robust trust threshold (τ* ≈ 0.68) operating as a behavioral phase transition: below this level, cooperation collapses; above it, participation becomes self-sustaining. Cross-country evidence from 274 organizations across 155 countries confirms consensus thresholds (C* ≈ 0.59), while analysis of 158,763 observations validates dual benefit mechanisms. The multiplicative structure explains why partial reforms fail: weakness in any single component drives overall sustainability toward zero. Applied to health insurance, this framework distinguishes conventional systems—Bismarckian employment-based, Beveridgean tax-financed, and commercial health insurance from sustainable systems like participatory community-based microinsurance that satisfy all three Trinity Law conditions through participatory design, transparent governance, and aligned incentives. The persistent UHC gap reflects not implementation failures but fundamental design incompatibilities that the Trinity Law makes explicit. This entry has three objectives: first, it states the Trinity Law conditions; second, it summarizes the empirical evidence for each component; third, it applies the framework to classify major health insurance models. Supporting datasets and code are available in the referenced Zenodo repositories. The term ‘law’ follows the tradition of social science regularities like the ‘law of demand’: a robust empirical pattern with strong predictive validity, not a claim to physical certainty.
- Open Access
Breaking the Mortality Curve: Investment-Driven Acceleration in Life Expectancy and Insurance Innovation
Capital investment in longevity science—research targeting the biological processes of aging through interventions like cellular reprogramming, AI-driven drug discovery, and biological age monitoring—may create significant divergence between traditional actuarial projections and emerging mortality improvements. This paper examines how accelerating investment in life extension technologies affects mortality improvement trajectories beyond conventional actuarial assumptions, building on the comprehensive investment landscape analysis documented in “Investors in Longevity” supported by venture capital databases, industry reports, and regulatory filings. We introduce an Investment-Adjusted Mortality Model (IAMM) that incorporates capital allocation trends as leading indicators of mortality improvement acceleration. Under high-investment scenarios (annual funding of USD 15+ billion in longevity technologies), current insurance products may significantly underestimate longevity risk, creating potential solvency challenges. Our statistical analysis demonstrates that investment-driven mortality improvements—actual reductions in death rates resulting from new anti-aging interventions—could exceed traditional projections by 18–31% by 2040. We validate our model by backtesting historical data, showing improved predictive performance (35% reduction in MAPE) compared to traditional Lee–Carter approaches during periods of significant medical technology advancement. Based on these findings, we propose modified insurance structures, including dynamic mortality-linked products and biological age underwriting, quantifying their effectiveness in reducing longevity risk exposure by 42–67%. These results suggest the need for actuarial science to incorporate investment dynamics in response to the changing longevity investment environment detailed in “Investors in Longevity”. The framework presented provides both theoretically grounded and empirically tested tools for incorporating investment dynamics into mortality projections and insurance product design, addressing gaps in current risk management approaches for long-term mortality exposure.
Open AccessBreaking the Mortality Curve: Investment-Driven Acceleration in Life Expectancy and Insurance Innovation
Capital investment in longevity science—research targeting the biological processes of aging through interventions like cellular reprogramming, AI-driven drug discovery, and biological age monitoring—may create significant divergence between traditional actuarial projections and emerging mortality improvements. This paper examines how accelerating investment in life extension technologies affects mortality improvement trajectories beyond conventional actuarial assumptions, building on the comprehensive investment landscape analysis documented in “Investors in Longevity” supported by venture capital databases, industry reports, and regulatory filings. We introduce an Investment-Adjusted Mortality Model (IAMM) that incorporates capital allocation trends as leading indicators of mortality improvement acceleration. Under high-investment scenarios (annual funding of USD 15+ billion in longevity technologies), current insurance products may significantly underestimate longevity risk, creating potential solvency challenges. Our statistical analysis demonstrates that investment-driven mortality improvements—actual reductions in death rates resulting from new anti-aging interventions—could exceed traditional projections by 18–31% by 2040. We validate our model by backtesting historical data, showing improved predictive performance (35% reduction in MAPE) compared to traditional Lee–Carter approaches during periods of significant medical technology advancement. Based on these findings, we propose modified insurance structures, including dynamic mortality-linked products and biological age underwriting, quantifying their effectiveness in reducing longevity risk exposure by 42–67%. These results suggest the need for actuarial science to incorporate investment dynamics in response to the changing longevity investment environment detailed in “Investors in Longevity”. The framework presented provides both theoretically grounded and empirically tested tools for incorporating investment dynamics into mortality projections and insurance product design, addressing gaps in current risk management approaches for long-term mortality exposure.
- Open Access
- 19 May 2025
- Published by MDPI AG in Preprints.org
Actuaries vs. Eternity: The Widening Gap Between Fast-Moving Lifespan Technologies and Change-Resistant Risk Models
The accelerating frontier of human longevity—driven by advances in cellular reprogramming, real-time biological monitoring, and AI-enabled drug discovery—is reshaping the possibilities of lifespan and healthspan. However, the institutional systems that manage financial risk over the life course—particularly actuarial models, pensions, and insurance—have failed to evolve in parallel. This paper explores the structural lag between rapidly advancing lifespan technologies and the static risk frameworks that underpin retirement security and social protection. It introduces the concept of translational actuarialism, a novel framework for re-aligning insurance and pension systems with biological innovation. Through real-world cases, conceptual models, and policy proposals, the paper maps the widening disconnect between what is biologically possible and what is institutionally prepared—arguing that without systemic adaptation, even the most transformative technologies may be slowed, distorted, or rendered inaccessible. Bridging this gap is not merely a technical task; it is a societal imperative.
- 19 May 2025
- Published by MDPI AG in Preprints.org
Open AccessActuaries vs. Eternity: The Widening Gap Between Fast-Moving Lifespan Technologies and Change-Resistant Risk Models
The accelerating frontier of human longevity—driven by advances in cellular reprogramming, real-time biological monitoring, and AI-enabled drug discovery—is reshaping the possibilities of lifespan and healthspan. However, the institutional systems that manage financial risk over the life course—particularly actuarial models, pensions, and insurance—have failed to evolve in parallel. This paper explores the structural lag between rapidly advancing lifespan technologies and the static risk frameworks that underpin retirement security and social protection. It introduces the concept of translational actuarialism, a novel framework for re-aligning insurance and pension systems with biological innovation. Through real-world cases, conceptual models, and policy proposals, the paper maps the widening disconnect between what is biologically possible and what is institutionally prepared—arguing that without systemic adaptation, even the most transformative technologies may be slowed, distorted, or rendered inaccessible. Bridging this gap is not merely a technical task; it is a societal imperative.
- Open Access
- 16 May 2025
- Published by MDPI AG in Preprints.org
Longevity Technology Transfer: From Laboratory to Marketplace
The leap from laboratory to marketplace represents the critical chasm in longevity technology innovation. While scientific breakthroughs in aging biology continue to accelerate (López-Otín et al., 2023; DePinho et al., 2024), the commercialization pathway remains fragmented, creating a unique "valley of death" where promising discoveries often fail to reach consumers despite substantial investment interest (Campisi et al., 2019). At stake is a projected $46.62 billion market by 2033 (Business Research Insights, 2024) that could revolutionize healthcare by shifting from disease treatment to prevention of aging itself—potentially the most transformative healthcare paradigm since antibiotics (Deloitte, 2024). The implications of successful longevity technology commercialization extend far beyond the healthcare sector, as increased lifespans would necessitate dramatic changes in workforce participation to compensate for declining new entrants to the labor force (Papapetrou & Tsalaporta, 2020), restructuring of pension and insurance systems that collectively manage trillions of dollars (Amaglobeli et al., 2019), and fundamental adjustments to social structures across developed economies (Grand View Research, 2024).
- 16 May 2025
- Published by MDPI AG in Preprints.org
Open AccessLongevity Technology Transfer: From Laboratory to Marketplace
The leap from laboratory to marketplace represents the critical chasm in longevity technology innovation. While scientific breakthroughs in aging biology continue to accelerate (López-Otín et al., 2023; DePinho et al., 2024), the commercialization pathway remains fragmented, creating a unique "valley of death" where promising discoveries often fail to reach consumers despite substantial investment interest (Campisi et al., 2019). At stake is a projected $46.62 billion market by 2033 (Business Research Insights, 2024) that could revolutionize healthcare by shifting from disease treatment to prevention of aging itself—potentially the most transformative healthcare paradigm since antibiotics (Deloitte, 2024). The implications of successful longevity technology commercialization extend far beyond the healthcare sector, as increased lifespans would necessitate dramatic changes in workforce participation to compensate for declining new entrants to the labor force (Papapetrou & Tsalaporta, 2020), restructuring of pension and insurance systems that collectively manage trillions of dollars (Amaglobeli et al., 2019), and fundamental adjustments to social structures across developed economies (Grand View Research, 2024).
- Open Access
- 14 May 2025
- Published by MDPI AG in Preprints.org
Breaking the Mortality Curve: Investment-Driven Acceleration in Life Expectancy and Insurance Innovation
Capital investment in longevity science is creating an unprecedented disconnect between traditional actuarial projections and emerging biological reality. This paper examines how accelerating investment in life extension technologies fundamentally alters mortality improvement trajectories beyond conventional actuarial assumptions. We introduce an Investment-Adjusted Mortality Model (IAMM) that incorporates capital allocation trends as leading indicators of mortality improvement acceleration. Our statistical analysis demonstrates that under high-investment scenarios, current insurance products may significantly underestimate longevity risk, creating potential solvency challenges. We validate our model through rigorous backtesting against historical data, showing superior predictive performance compared to traditional approaches. Based on these findings, we propose innovative insurance structures including dynamic mortality-linked products and biological age underwriting, quantifying their effectiveness in reducing longevity risk exposure. These results highlight the urgent need for actuarial science to evolve in response to the rapidly changing longevity investment environment detailed in "Investors in Longevity" [1].
- 14 May 2025
- Published by MDPI AG in Preprints.org
Open AccessBreaking the Mortality Curve: Investment-Driven Acceleration in Life Expectancy and Insurance Innovation
Capital investment in longevity science is creating an unprecedented disconnect between traditional actuarial projections and emerging biological reality. This paper examines how accelerating investment in life extension technologies fundamentally alters mortality improvement trajectories beyond conventional actuarial assumptions. We introduce an Investment-Adjusted Mortality Model (IAMM) that incorporates capital allocation trends as leading indicators of mortality improvement acceleration. Our statistical analysis demonstrates that under high-investment scenarios, current insurance products may significantly underestimate longevity risk, creating potential solvency challenges. We validate our model through rigorous backtesting against historical data, showing superior predictive performance compared to traditional approaches. Based on these findings, we propose innovative insurance structures including dynamic mortality-linked products and biological age underwriting, quantifying their effectiveness in reducing longevity risk exposure. These results highlight the urgent need for actuarial science to evolve in response to the rapidly changing longevity investment environment detailed in "Investors in Longevity" [1].